Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Klotho Neurosciences ( (KLTO) ) has issued an update.
On July 22, 2025, Klotho Neurosciences announced a partnership with AAVnerGene Inc. to advance its gene therapy candidates using AAVnerGene’s cutting-edge AAV manufacturing and delivery technologies. This collaboration aims to enhance the efficiency, cost-effectiveness, and efficacy of Klotho’s therapies for diseases like Alzheimer’s, Parkinson’s, and ALS. The partnership is expected to address current challenges in AAV gene therapy, such as high costs and dose-related toxicity, by leveraging AAVnerGene’s proprietary platforms to improve manufacturing processes and tissue targeting. This strategic move is anticipated to strengthen Klotho’s position in the gene therapy market and potentially bring more affordable and innovative treatments to patients.
More about Klotho Neurosciences
Klotho Neurosciences, Inc. is a biogenetics company focused on developing innovative cell and gene therapies using a protein derived from the patented ‘anti-aging’ human Klotho gene. The company aims to transform the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer’s, and Parkinson’s disease through its proprietary cell and gene therapy programs and genomics-based diagnostic assays.
Average Trading Volume: 43,946,194
Technical Sentiment Signal: Buy
Current Market Cap: $67.99M
See more data about KLTO stock on TipRanks’ Stock Analysis page.